Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

Trial ID or NCT#

NCT00766116

Status

not recruiting iconNOT RECRUITING

Purpose

This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back after treatment.

Official Title

A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML

Eligibility Criteria

Ages Eligible for Study: 18 Years to 90 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Diagnosis of Relapsed AML - Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and life expectancy > 3 months - ≥ 18 years old - Previously untreated for current AML relapse - Adequate organ function - Written informed consent
Exclusion Criteria:
  1. - Pregnant or breast-feeding women - Growth factors that support platelet or white cell number or function must not have been administered within the past 7 days - Currently receiving another investigational drug - Currently receiving other anti-cancer agents - Uncontrolled infection - HIV positive - Received previous therapy with either Mylotarg or 5-azacitidine
View All Criteria
Show Less

Investigator(s)

Rondeep Brar
Rondeep Brar
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Hematology
Lauren Maeda
Lauren Maeda
Hematologist, Lymphoma specialist, Hematologist-Oncologist
Clinical Associate Professor, Medicine - Oncology

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061

View on ClinicalTrials.gov